Molecular Tumor Board at the Center for Personalized Medicine Tübingen
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: no intervention.
- Who it may be relevant to
- Registry conditions: Advanced Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study
Overview
Molecular Tumor Board at the Center for Personalized Medicine
Detailed description
Molecular Tumor Board at the Center for Personalized Medicine The study objectives are
* To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care * To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) * To prospectively assess patient-reported outcome of MTB patients * To evaluate compliance to MTB suggestions in routine clinical care
Interventions
- Other no intervention
observational study
Primary outcome measures
- Progression-free survival [Time frame: 6 months]
Secondary outcome measures (1)
- Overall survival [Time frame: an average of 1 year]
Eligibility criteria
Inclusion criteria
- Given informed consent ("broad consent" of the University Hospital Tübingen)
- ≥ 18 years of age
- Clinical indication for a referral to Molecular Tumor Board by the treating physician
Exclusion criteria
- The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Germany · 1 center
- University Hospital Tübingen — Tübingen
Identifiers
NCT: NCT03503149 · ZPM-001